
Opinion|Videos|May 27, 2025
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
Author(s)Neal Shore, MD, FACS
Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency.
Advertisement
Episodes in this series

Clinical Implications for PSA Monitoring
Key Themes:
- Real-world implications for urologists monitoring patients on darolutamide plus ADT
- Importance of sensitive PSA assays
- Potential for PSA kinetics to guide treatment decisions
Expert Insights:
- Dr Shore provided guidance on how these findings might influence the way urologists monitor and interpret PSA trends in patients receiving darolutamide plus ADT.
He emphasized the importance of using appropriately sensitive assays and how PSA kinetics could inform treatment intensity or surveillance strategies.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Unmet needs and emerging solutions in MRI-guided prostate cancer care
2
HHS requests testosterone therapy label updates, citing new safety data
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5












